Skip Nav Destination
Issues
1 December 2021
-
Cover Image
Cover Image
Pancreatic ductal adenocarcinoma (PDAC) is considered immunologically “cold,” and treatment with immune checkpoint blockade targeting PD-1/PD-L1 is only effective in a subset of patients. Karamitopoulou et al. use an automated system, in addition to next-generation sequencing, to analyze the tumor microenvironment (TME) from patients with microsatellite-stable (MSS) and -instable (MSI) PDAC. Distinct patterns of PD-1/PD-L1 expression that correlate with different patient outcomes and characteristics of the TME, including immune composition and cell proximity, are identified. These data provide a deeper understanding of the PDAC TME and its heterogeneity and could aid in treatment decisions for patients with PDAC. Read more in this issue on page 1439. Original image from Fig. 4. Artwork by Lewis Long.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2326-6066
EISSN 2326-6074
Issue Sections
Journal Archive
Cancer Immunology Research (2013-Present)
(ISSN 2326-6066) Published monthly since 2013.Cancer Immunity (2001-2013; volumes 1-13)
(EISSN 1424-9634) Published periodically from 2001-2013.Table of Contents
What We’re Reading
In the Spotlight
Review
Research Articles
Glioblastoma Cell–Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance
Ziwei Li; Xiangqi Meng; Pengfei Wu; Caijun Zha; Bo Han; Lulu Li; Nan Sun; Tengfei Qi; Jie Qin; Yangong Zhang; Kaifu Tian; Shupeng Li; Changxiao Yang; Lejia Ren; Jianguang Ming; Pandeng Wang; Yifei Song; Chuanlu Jiang; Jinquan Cai
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1
Chahrazade Kantari-Mimoun; Sarah Barrin; Lene Vimeux; Sandrine Haghiri; Claire Gervais; Sandy Joaquina; Joerg Mittelstaet; Nadine Mockel-Tenbrinck; Ali Kinkhabwala; Diane Damotte; Audrey Lupo; Mathilde Sibony; Marco Alifano; Elisabetta Dondi; Nadège Bercovici; Alain Trautmann; Andrew D. Kaiser; Emmanuel Donnadieu
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
Hikmat H. Assi; Chihunt Wong; Kimberly A. Tipton; Li Mei; Ken Wong; Jennifer Razo; Chanty Chan; Bruce Howng; Jason Sagert; Michael Krimm; Linnea Diep; Andrew Jang; Margaret T. Nguyen; Nicole Lapuyade; Victoria Singson; Ruth Villanueva; Madan Paidhungat; Shouchun Liu; Vangipuram Rangan; Olga Vasiljeva; James W. West; Jennifer H. Richardson; Bryan Irving; Dylan Daniel; Marcia Belvin; W. Michael Kavanaugh
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
Xia Bu; Vikram R. Juneja; Carol G. Reynolds; Kathleen M. Mahoney; Melissa T. Bu; Kathleen A. McGuire; Seth Maleri; Ping Hua; Baogong Zhu; Sarah R. Klein; Edward A. Greenfield; Philippe Armand; Jerome Ritz; Arlene H. Sharpe; Gordon J. Freeman
CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
Mariona Cabo; Sara Santana-Hernández; Marcel Costa-Garcia; Anna Rea; Roberto Lozano-Rodríguez; Michelle Ataya; Francesc Balaguer; Manel Juan; Maria C. Ochoa; Silvia Menéndez; Laura Comerma; Ana Rovira; Pedro Berraondo; Joan Albanell; Ignacio Melero; Miguel López-Botet; Aura Muntasell
Advertisement